
## Ministry of Food and Drug Safety Daejeon Regional Office of Food and Drug Safety

166, Cheongsa-ro, Seo-gu, Daejeon, Korea Tel: 82-42-480-8710, Fax; 82-42-480-8715

### Certificate of a Pharmaceutical Product



- Exporting (certifying) country: Republic of Korea

└ Importing (requesting) country : Chile

1. Applicant (=Product-license holder)

(This certificate shall not be issued to others than the product-license holder)

- Name: Korea United Pharm. Inc.

- Address: 107 Gongdan-ro, Yeonseo-myeon, Sejong-si, Republic of Korea

2. Name and dosage form of product

: Bleomycin Sulfate for Injection 15 units

Product Name in Korean: 브로이신에스주

2.1. Number of product license and date of issue

: 1752-574 / May 12, 1998

2.2. Active ingredient(s) and amount(s) per unit dose

(For Complete quantitative composition including excipients, see attached.)

: Each vial contains


Bleomycin Sulfate · · · · 15 units (Potency)





3. Is this product licensed to be placed on the market for use in the exporting	g
country?	
$\neg$ Yes (V) $\Rightarrow$ fill out section A, omit section B.	
$^{\perp}$ No ( ) $\Rightarrow$ omit section A, fill out section B.	_,
A.1. Is this product actually on the market in the exporting country?	
Yes(V)/No()/Unknown()	
A.2. Is Summary Technical Basis of Approval appended?	
Yes( ) / No( V )	
A.3. Is the attached, officially approved product information complete and consonant with	ı
the license ?: Yes( ) / No( ') / Not provided( V )	
B.1. Why is marketing authorization lacking?	
not required (just Applicant's option, even possible) ( )	
⊢ not requested (not reviewed for marketing) ( )	
├ under consideration ( )	
└ refused ( )	
B.2. Remarks (the reason not requesting registration):	
2.4. Status of product-license holder a (V) manufactures the dosage form	
b ( ) consigns partially the manufacturing process to other company	
- the manufacturer's	
· Name:	w
· Address:	
· Consigned process:	
c ( ) is not involved in manufacturing process:	
- the manufacturer's	
· Name:	
· Address:	
· Consigned process:	





- 3.1. Periodicity of routine inspection(years): 3 years

  Inspection is determined by risk-based assessment under the provisions of the Pharmaceutical Affairs Act.
- 3.2. Has the manufacture of this type of dosage form been inspected? : YES
- 3.3. Do the facilities and operations conform to the WHO-GMP? : Yes, It conforms to PIC/S and WHO GMP.
- 4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product: YES

<b>※</b>	Attached,	if necessary	: approved	product in	nformation (	(O)
			•			
	•••		• • • • • • • • • • • • • • • • • • • •		• • • • • • • • • • • • • • • • • • • •	

Issued date: <u>FEB. 03, 2017</u>

Certified by

of General Services Division

Daejeon Regional Food & Drug Administration





# PRODUCT NAME: BLEOMYCIN SULFATE FOR INJECTION 15 UNITS

Ingredients Per Vial

Active Ingredient:

Bleomycin Sulfate 15 units

(Potency)

Inactive Ingredients:

Water for Injection\*

q.s. to 1.5 mL

<sup>\*</sup> Evaporated during manufacturing.





#### **APOSTILLE**

(Convention de La Haye du 5 octobre 1961)

1. Country: Republic of Korea

This public document

2 has been signed by Director

3. acting in the capacity of Director

4. bears the seal/stamp of Daejeon Regional Food and Drug Administration

## Certified -

7. by The Ministry of Foreign Affairs 8. No. XXA201703JE2PN

9. Seal / stamp

10. Signature



Kim Byoung Ho

CERTIFICO QUE LA PRESENTE FOTOCOPIA ES FIEL DEL ORIGINAL TENIDO A LA VISTA, COMPUESTO DE FOJAS, Y QUE DEVUELVO AL SOLICITANTE.

STGO. 0 1 MAR 2017

JUAN RICARDO SAN MARTIN URREJOLA NOTARIO PUBLICO SANTIAGO



Comment of the second